Market Overview

UPDATE: Piper Jaffray Raises PT to $118 on Edwards Lifesciences on Lower Risks Ahead

Share:
Related EW
Asia Is Giving These ETFs A Major Boost
Earnings Scheduled For July 26, 2017

Piper Jaffray reiterated its Overweight rating on Edwards Lifesciences (NYSE: EW) and increased its price target on shares from $90 to $118 in a research report published Friday.

Piper Jaffray noted, "We are raising our price target on EW reflecting the reduction in risk inherent with the positive national coverage decision (NCD), positive FDA panel meeting on high-risk patients, and the removal of uncertainty related to the outcome of the Supreme Court decision on the Affordable Care Act (ACA)."

Edwards Lifescience closed at $104.44 on Thursday.

Latest Ratings for EW

DateFirmActionFromTo
Jul 2017BarclaysMaintainsEqual-Weight
Jul 2017Morgan StanleyMaintainsOverweight
May 2017Goldman SachsInitiates Coverage OnBuy

View More Analyst Ratings for EW
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Reiteration Pre-Market Outlook Analyst Ratings

 

Related Articles (EW)

View Comments and Join the Discussion!
Loading...
Loading...